Principal Street Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$887K Buy
5,806
+79
+1% +$12.1K 0.14% 86
2025
Q4
$790K Sell
5,727
-593
-9% -$77.7K 0.13% 94
2025
Q3
$810K Sell
6,320
-5,908
-48% -$721K 0.13% 95
2025
Q2
$1.48M Buy
12,228
+6,148
+101% +$693K 0.15% 90
2025
Q1
$678K Sell
6,080
-1
-0% -$106 0.13% 103
2024
Q4
$592K Buy
6,081
+1
+0% +$107 0.12% 113
2024
Q3
$647K Hold
6,080
0.11% 116
2024
Q2
$647K Hold
6,080
0.12% 109
2024
Q1
$621K Buy
6,080
+4,091
+206% +$419K 0.12% 117
2023
Q4
$201K Buy
+1,989
New +$192K 0.05% 205
2023
Q1
Sell
-4,065
Closed -$369K 236
2022
Q4
$369K Sell
4,065
-354
-8% -$29.8K 0.09% 148
2022
Q3
$336K Buy
4,419
+1,106
+33% +$91.7K 0.09% 149
2022
Q2
$280K Buy
+3,313
New +$291K 0.07% 170

Other funds holding NVS

Principal Street Partners's NVS Position: Q1 2026 in Review

Principal Street Partners increased its Novartis (NVS) stake by 1.4% in Q1 2026, buying an estimated $12.1K and bringing the position to 5,806 shares worth $887K. The position accounts for 0.14% of the portfolio, ranked #86.

Principal Street Partners first reported a position in NVS in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.48M in Q2 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Principal Street Partners held 5,806 shares of Novartis worth $887K as of Q1 2026.
  • Principal Street Partners bought 79 Novartis shares in Q1 2026, an estimated $12.1K.
  • Novartis made up 0.14% of Principal Street Partners's portfolio in Q1 2026, its #86 holding.
  • Principal Street Partners first reported a position in Novartis in Q2 2022 and has held it in 13 quarters since.
  • Principal Street Partners's Novartis position peaked at $1.48M in Q2 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Principal Street Partners's 13F filing for Q1 2026, filed 15 May 2026.